Short Interest in Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Drops By 12.3%

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 6,400 shares, a decrease of 12.3% from the February 28th total of 7,300 shares. Based on an average daily volume of 81,100 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are sold short.

Enzon Pharmaceuticals Price Performance

Shares of Enzon Pharmaceuticals stock opened at $0.11 on Wednesday. Enzon Pharmaceuticals has a 1 year low of $0.06 and a 1 year high of $0.24. The firm has a market cap of $8.15 million, a price-to-earnings ratio of 10.99 and a beta of 0.26. The company has a 50-day moving average of $0.12 and a 200 day moving average of $0.12.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.